Jpmorgan Chase & CO Glycomimetics Inc Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Glycomimetics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 141 shares of GLYC stock, worth $36. This represents 0.0% of its overall portfolio holdings.

Number of Shares

141

Previous 151 6.62%

Holding current value

$36

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Dec 26, 2024	SELL	$0.16 - $0.32 $1 - $3	-10 Reduced 6.62%	141 $0
Q3 2024 Nov 08, 2024	SELL	$0.16 - $0.32 $1 - $3	-10 Reduced 6.62%	141 $0
Q2 2024 Dec 26, 2024	BUY	$0.24 - $3.04 $2 - $30	10 Added 7.09%	151 $0
Q2 2024 Aug 12, 2024	SELL	$0.24 - $3.04 $20,273 - $256,797	-84,473 Reduced 99.82%	151 $0
Q1 2024 Dec 26, 2024	BUY	$2.55 - $3.49 $215,431 - $294,845	84,483 Added 59917.02%	84,624 $253,000
Q1 2024 May 10, 2024	BUY	$2.55 - $3.49 $211,678 - $289,708	83,011 Added 5146.37%	84,624 $253,000
Q4 2023 Dec 26, 2024	BUY	$1.13 - $2.54 $1,663 - $3,738	1,472 Added 1043.97%	1,613 $3,000
Q4 2023 Feb 12, 2024	BUY	$1.13 - $2.54 $1,296 - $2,913	1,147 Added 246.14%	1,613 $3,000
Q3 2023 Nov 14, 2023	SELL	$1.29 - $1.73 $416 - $558	-323 Reduced 40.94%	466 $0
Q2 2023 Aug 11, 2023	SELL	$1.21 - $2.08 $6,511 - $11,192	-5,381 Reduced 87.21%	789 $1,000
Q1 2023 May 11, 2023	BUY	$1.25 - $4.05 $7,712 - $24,988	6,170 New	6,170 $7,000
Q2 2022 Aug 11, 2022	SELL	$0.54 - $1.15 $792 - $1,687	-1,467 Reduced 99.93%	1 $0
Q1 2022 May 11, 2022	BUY	$1.0 - $1.58 $230 - $363	230 Added 18.58%	1,468 $2,000
Q4 2021 Feb 10, 2022	SELL	$1.44 - $2.14 $42,351 - $62,939	-29,411 Reduced 95.96%	1,238 $2,000
Q3 2021 Nov 12, 2021	BUY	$1.8 - $2.39 $55,168 - $73,251	30,649 New	30,649 $67,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.7M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.6M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Glycomimetics Inc Transaction History